Skip to main content
BRS1 — Neurotransmitter Regulation

BRS1 - Neurotransmitter Regulation​

(Neurotransmitter Signalling, Chemical Communication & Structural Organisation)

All Mechanisms of BRS1

Ambition​

Maintain continuous, balanced neurotransmitter signalling across monoaminergic, cholinergic and GABA–glutamate systems, supported by membrane-lipid integrity, so the brain sustains attention, arousal, motivation, emotional regulation and behavioural control without drifting into depletion, broader signalling imbalance or excitation–inhibition mismatch.

Rationale for inclusion as a distinct BRS​

Neurotransmitter regulation was defined as a distinct BRS because it coordinates the brain’s chemical-communication infrastructure and supporting physical organisation: monoaminergic signalling, cholinergic function, GABA–glutamate balance, and the membrane-lipid environment in which receptors and transporters operate, and the selective formation, retention, remodelling and elimination of synaptic connections. These interconnected processes jointly determine attention, arousal, motivation, emotional regulation and behavioural control. BRS1 is therefore represented as the primary signalling system of the framework: other BRSs can constrain it through precursor supply, cofactors, energy, redox tone or stress allocation, but they do not replace transmitter-specific enzymatic and receptor regulation. It is not presented as a single-neurotransmitter explanation for brain-related conditions, but as a coherent signalling architecture with independently assessed dietary and behavioural routes with biologically traceable dependencies across the wider regulatory network.

Therapeutic Area Research​

ADHD is the first fully mapped therapeutic area within the BRAIN Framework, providing a proof of concept for an adaptive biological architecture linking nutrition, biology and function. The same framework is designed to expand across additional therapeutic areas through the shared Phenome Registry.

Dietary and Lifestyle Levers​

Stable neurotransmitter signalling needs more than precursor supply. Shared amino-acid pools, dietary patterns and lifestyle collectively determine how effectively neurotransmitter systems can synthesise, regulate and sustain signalling across changing cognitive and physiological demands.

The following dietary guidance summarises the principal dietary patterns, shared nutrient pools and representative food sources that support the biological constraints underlying BRS1. The guidance reflects shared biological principles rather than prescriptive recommendations; individual requirements and optimal dietary patterns will vary according to physiology, health status and the wider diet.

Functional Mechanisms​

Monoaminergic, cholinergic, membrane-lipid, and GABA–glutamate mechanisms jointly govern attention, drive, memory, and excitatory–inhibitory balance. Together they set whether precursor supply, receptor environments, and daily signalling tone can support stable function as demand and circadian timing shift.

Cross-BRS Dependencies​

Neurotransmitter regulation depends upon the coordinated performance of multiple Biological Regulatory Systems rather than a single isolated pathway. Cross-BRS Dependencies describe these systems-level relationships, explaining how upstream adaptive biology shapes the biological environment within which resilient neurotransmitter regulation can be maintained during changing physiological demands.

  • (BRS4 → BRS1) Bioenergetic Support for NeurotransmissionOpen →
  • (BRS3 → BRS1) Inflammatory Modulation of Neurotransmitter SystemsOpen →
  • (BRS6 → BRS1) Stress-Axis and Autonomic Shaping of NeurotransmissionOpen →
  • (BRS2 → BRS1) One-Carbon Support for Neurotransmitter RegulationOpen →
  • (BRS5 → BRS1) Gut–Vagal Modulation of Neurotransmitter RegulationOpen →

Specific Mechanisms​

Specific Mechanisms (SMs) are interpretation layers — context-specific readings of stable BRS1 biology grounded in connected PMs, FMs, and KCs. They provide additional biological context for applying the BRAIN Framework. Current SM categories include SM-SNP (genetic variation), SM-CROSS (multi-BRS interpretive concepts), SM-Male and SM-Female (sex-specific biology), SM-Lifestage (e.g. childhood, pregnancy, older adulthood), and SM-Pattern (e.g. vegan, vegetarian, ketogenic). Functional phenotype interpretation is handled via the Phenome Registry rather than SM-PHEN pages. Individual SMs may be combined to create richer biological profiles and support future precision-nutrition applications.

SM-CROSS​

SM-SNP​

References​

[1] MacDonald et al. (2024). The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models. Dopaminergic dysfunction in ADHD does not support a simple global hypo-dopaminergic model; alterations vary by subtype, stage, and brain region.

[2] Wang et al. (2019). Dietary Profiles, Nutritional Biochemistry Status, and Attention-Deficit/Hyperactivity Disorder: Path Analysis for a Case-Control Study. Meal-level amino-acid sufficiency may support catecholaminergic and serotonergic precursor pools relevant to ADHD attention pathways.

[3] F W Reimherr & M Ward (1987). An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. A small open trial of L-tyrosine in 12 adults produced an initial response that disappeared as tolerance developed; it does not support sustained L-tyrosine supplementation for ADHD.

[4] Oades et al. (2010). The Role of Serotonin in Attention-Deficit Hyperactivity Disorder (ADHD). Role of serotonin in ADHD.

[5] Banerjee & Nandagopal (2015). Does serotonin deficit mediate susceptibility to ADHD?. Serotonin deficit susceptibility in ADHD.

[6] Shaw et al. (2014). Emotion Dysregulation in Attention Deficit Hyperactivity Disorder. Emotion dysregulation in attention deficit hyperactivity disorder.

[7] Derbyshire & Maes (2023). The Role of Choline in Neurodevelopmental Disorders—A Narrative Review Focusing on ASC, ADHD and Dyslexia. Low choline intakes and altered choline status in neurodevelopmental subgroups relevant to attention and learning.

[8] Johansson et al. (2013). Decreased binding capacity (B max) of muscarinic acetylcholine receptors in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD). Decreased muscarinic acetylcholine receptor binding in neurodevelopmental contexts.

[9] Pei-Chen Chang (2021). Personalised medicine in child and Adolescent Psychiatry: Focus on omega-3 polyunsaturated fatty acids and ADHD. Focus on omega-3 polyunsaturated fatty acids and ADHD.

[10] Huss et al. (2010). Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study. PUFA, magnesium, and zinc supplementation studied in children seeking medical attention for behavioural symptoms.

[11] Maltezos et al. (2014). Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study. Low glutamate in critical brain areas correlates with low Barkley attention scale scores.

[12] Edden et al. (2012). Reduced GABA Concentration in Attention-Deficit/Hyperactivity Disorder. Reduced GABA concentration in attention-deficit/hyperactivity disorder.

[13] Puts et al. (2020). Reduced striatal GABA in unmedicated children with ADHD at 7T. Reduced striatal GABA in unmedicated children with ADHD.

[14] Mamiya et al. (2021). Precision Medicine Care in ADHD: The Case for Neural Excitation and Inhibition. Neural excitation and inhibition balance framing.

[15] Harris et al. (2012). Synaptic energy use and supply. Demonstrated that synaptic signalling accounts for the largest proportion of neuronal energy expenditure and that sustained neurotransmission depends upon adequate mitochondrial ATP supply during increasing energetic demand.

[16] Picard et al. (2015). Mitochondrial synapses: intracellular communication and signal integration. Reframed mitochondria as dynamic signalling and energetic organelles that coordinate cellular energetics with neuronal activity, supporting the interpretation of BRS4 as an upstream enabling system preserving BRS1 adaptive performance.

[17] Slavich & Irwin (2014). From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Established that psychological and physiological stressors activate inflammatory signalling capable of reshaping central nervous system function through coordinated immune, neuroendocrine and neurochemical pathways. This supports the framework interpretation that chronic inflammatory activation can become a principal upstream constraint on BRS1 performance during sustained physiological demand.

[18] Savitz et al. (2020). The kynurenine pathway: a finger in every pie. Demonstrated that immune activation reshapes neurotransmitter regulation through the kynurenine pathway and broader neuroimmune interactions, influencing both monoaminergic signalling and excitation–inhibition balance. This supports the BRAIN Framework interpretation that maintaining immune regulation preserves the biological environment required for resilient monoaminergic and excitation–inhibition regulation within BRS1.

[19] McEwen et al. (1998). Protective and damaging effects of stress mediators. Established allostatic load as cumulative biological wear arising when stress mediators protect or damage brain structure and function under sustained adaptive demand — supporting the framework interpretation that dysregulated neuroendocrine load may become a principal constraint on BRS1 performance.

[20] McEwen et al. (2006). Protective and damaging effects of stress mediators in health and disease. Positioned the brain as the central interpreter and target of stress-mediated adaptive regulation — supporting the framework interpretation that BRS6 coordinates how allostatic load is allocated across integrated biological systems including neurotransmitter regulation within BRS1.

[21] Thayer et al. (2012). A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health.. Demonstrated intimate coupling between autonomic regulatory capacity, stress neurobiology and central nervous system function — supporting the interpretation of BRS6 autonomic stability as an upstream enabler of BRS1 adaptive performance during sustained physiological demand.

[22] Chiang et al. (1996). S-Adenosylmethionine and methylation. Reviews S-adenosylmethionine as the principal cellular methyl donor and its roles in transmethylation pathways.

[23] Kennedy et al. (2016). B Vitamins and the Brain: Mechanisms, Dose and Efficacy—A Review. Reviews B-vitamin involvement in one-carbon metabolism and brain function; it does not establish a clinical BRS2 → BRS1 effect.

[24] Bravo et al. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Demonstrated that gut microbiota can modulate central neurochemical regulation through vagal signalling pathways — supporting the framework interpretation that impaired gut–brain communication may become a principal constraint on neurotransmitter regulation during sustained peripheral perturbation.

[25] Jaggar et al. (2020). You've got male: Sex and the microbiota-gut-brain axis across the lifespan. Synthesised how microbial metabolite and vagal signalling interact with central nervous system function — supporting the interpretation of BRS5 as an upstream enabling system preserving BRS1 adaptive performance during sustained physiological demand.